Healthcare & Medical
Health insurance, medical billing, and coverage decisions, broken down so surprise bills are less likely to surprise you.
Healthcare & Medical articles
Boston Mastered Biotech's First Era. One Founder's Move to California Is a Question About Its Second
A Harvard-and-MIT-trained founder who fits Boston's exact entrepreneurial profile built his biotech company in California instead. One anecdote isn't a migration, but it points at a real risk, the source of biotech's regional advantage may be shifting from wet-lab biology to computation.
One Year After the CDC Shooting, the Danger to Public Health Has Shifted From the Diseases It Fights to the Trust It Needs
A year after a gunman fired more than 180 rounds at CDC headquarters, killing a police officer, staff say they still feel targeted. The deepest damage wasn't the shattered windows, it was to the trust public health depends on to function at all.
The NIH Plans to Bar Visa-Holding Scientists From a Career-Making Grant. The Real Cost Is Retention, and It's Easy to Miss
The NIH plans to close its K99/R00 "Pathway to Independence" award to scientists on temporary visas, removing one of the few federal bridges from postdoc to independent faculty for international researchers. The policy has a real case behind it, and a cost that is real, delayed, and easy to miss.
The FDA Cleared a Melanoma Drug It Twice Rejected. The Approval Defers the Hard Question to a Trial Still Running
The FDA accelerated-approved Replimune's RP1 for advanced melanoma after two rejections and a contentious 10-3 advisory vote. The approval does not resolve whether RP1 itself drives the durable survival benefit seen in its single-arm trial, that question now falls to a confirmatory trial years from reporting.
A Relabeling Meant to Invite Competition Gave an Old AbbVie Drug Seven More Years Before Price Negotiation
A Public Citizen report says CMS treated AbbVie's decades-old Creon as freshly protected biologic innovation after a purely administrative reclassification, delaying Medicare price negotiation by seven years on a drug that cost the program $1.49 billion in 2024.
Tau May Harm Neurons by Running Their Mitochondria in Reverse. That's a Genuine New Lead, and a Familiar Long Shot
A Stanford-led study found that tau can drive electrons backward through neurons' mitochondria, generating the oxidative stress that damages them. The mechanism is specific and genuinely new, but it still faces the same distance from animal models to human treatment that has humbled nearly every Alzheimer's lead before it.
A Closed-Door Clinical-AI Demo Day With Regulators Shows Why Industry Engagement Is Both Necessary and Risky
Federal health officials held an unannounced, closed-door demo day with ten clinical-AI companies at FDA headquarters. The episode captures a real tension, regulators need to understand fast-moving technology firsthand, but private, selective access is the classic setup for regulatory capture.
Erica Schwartz Is Confirmed to Lead the CDC, on the Strength of What She Declined to Promise
The Senate confirmed Dr. Erica Schwartz to lead the CDC after she declined to say whether she would defend the agency's science against political pressure. That evasiveness was not a flaw in her candidacy, it was the mechanism that made her confirmable.
The Orphan-Drug Exemption Was Built for Small Markets. It Now Protects Blockbusters, Which Is Why It Guts Medicare's Savings
A new analysis finds that exempting orphan drugs from Medicare's drug-pricing pilots would erase most of their savings. The paradox unwinds once you see that the orphan label, meant for tiny markets, now also covers blockbusters like Keytruda.
In Prostate Cancer, a Better Test Finds Fewer Cancers. The MRI-Versus-Biopsy Debate Is Really About Overdiagnosis
Prostate cancer is extremely common and rarely deadly, a combination partly explained by overdiagnosis. Growing trial evidence favors MRI-first diagnosis over systematic biopsy precisely because it finds less indolent cancer, not more.
Prehabilitation for Frail Heart-Transplant Candidates Reframes Eligibility as a Movable Threshold, Not a Fixed Trait
A new in-patient exercise program helped previously ineligible, hospitalized heart-transplant candidates qualify for surgery. It reveals that frailty-based ineligibility is often a gap in the care pathway rather than a fixed fact about the patient, and it raises a hard question about a scarce resource.
Medicare Is Tightening Breakthrough-Device Payments and Speeding Their Coverage. Understanding the Difference Explains the Policy.
CMS finalized a rule eliminating shortcuts that let FDA breakthrough-designated devices skip proof of clinical improvement to earn extra Medicare payments. A separate move speeds coverage instead. Read as a package, it's a deliberate rebalancing, not a simple cut.
The 2026 Cyclospora Outbreak Records Its First Deaths, and Its Source, Scale, and Danger Are Each Less Simple Than They Appear
Michigan reported the first two U.S. deaths in a cyclospora surge with over 18,000 cases nationally. The source is not one contamination event, the count is both undercounted and unevenly tallied, and the danger concentrates in a vulnerable subgroup the "usually mild" description hides.
A Senate Bill Blocks Political Control of Research Grants. The Real Question Isn't Whether Politics Belongs, but Where.
A bipartisan Senate funding bill would temporarily block a White House proposal giving political appointees control over individual federal research grants. The real fight is about which level of the decision political accountability should reach, not whether it belongs at all.
The FDA's Advisers Backed a Drug They Couldn't Fully Interpret and Rejected One They Called a "Mirage." The Difference Is Trust.
Two FDA advisory committees faced imperfect evidence for two drugs in the same week and split in opposite directions. The deciding factor wasn't how much proof each had, but whether the proof could be believed.
Syphilis Is Curable With a Cheap, 80-Year-Old Shot. Every Reason It's Spreading Is a System Failure.
A single injection has cured syphilis for eighty years, yet congenital syphilis rates have risen more than 200% in five years. A national penicillin shortage, no substitute drug for pregnant patients, and gaps in surveillance explain why, not any failure of the medicine itself.
A Diabetes Group Fought for Editorial Independence in 2015. Now It's Suppressing Its Own. The Difference Is Who It Costs.
The American Diabetes Association defended a journal's editorial independence in 2015 when it was cheap. In 2026 it suppressed its own researchers when defending them risked its NIH funding relationship. The contrast reveals when institutional principle actually holds.
The FDA Halted Every Trial Using One Vector and Restored Only One. The Inconsistency Is More Defensible Than It Looks.
The FDA paused all of Sarepta's LGMD gene-therapy trials after deaths tied to a shared viral vector, then restored access disease by disease. The pattern looks inconsistent but reflects a real difference in how safety and benefit evidence behave.
Novo Nordisk's Drug Lowered Inflammation Perfectly. It Prevented Zero Heart Attacks. That Gap Is Why Outcomes Trials Exist.
Novo's ziltivekimab hit its inflammation targets precisely in a 6,300-patient trial but produced no reduction in heart attacks, strokes, or cardiovascular deaths. The gap between a moved surrogate and an unmoved outcome is the whole lesson.
Medicaid's New Exemption Is for People Too Sick to Work. Claiming It Requires the Very Capacity Being That Sick Takes Away.
CMS's medically-frail exemption from Medicaid work requirements now demands proof of functional incapacity, a documentation burden that falls hardest on the sickest enrollees it is meant to protect.
Is America's Drug-Supply Vulnerability China's Fault or Our Own? The Answer Is Both, and the Order Matters.
A market-failure argument and a national-security argument about pharmaceutical dependence on China are not rivals, they answer different questions, cause and stakes, and both have to be fixed together for either fix to hold.
Oil Shocks Make Some Medicines Pricier. The Weak Point Isn't Shipping, It's the Chemistry Itself.
A Unitaid analysis of a widely used HIV treatment finds that over 85% of oil-driven cost increases come from upstream petrochemical feedstocks and solvents, not transport, relocating a risk most supply-chain fixes do not address.
A Judge Declined to Pause Medicaid's New Work Rule. He Didn't Decide Whether It's Lawful, and That Distinction Is the Whole Story.
A federal judge denied a preliminary injunction against Medicaid's new work-requirement rule on procedural grounds, not on the merits, and the reasoning exposes a structural timing gap in how these legal challenges work.
Cassidy Traded His Vote for Assurances Once Before. Those Reportedly Broke. He Just Did It Again.
Senator Bill Cassidy cast a decisive committee vote for a vaccine-skeptic HHS nominee after securing private, unenforceable assurances, the same trade he made for RFK Jr., whose promises reportedly were not kept.
A Long Hospital Stay Doesn't Pause a Child's Development. It Spends a Part That Doesn't Come Back.
About a third of hospitalized children are unaccompanied for most of a 24-hour period. The real cost is a developmental window, not just loneliness.
A Non-Opioid Painkiller Reportedly Outperformed an Opioid. Before the IPO, It's Worth Asking What "Outperformed" Means.
Latigo's Phase 2 trial was powered against placebo. The opioid comparison carrying the IPO narrative is almost certainly descriptive, not proven.
Half of Life-Science PhDs Now Leave for Industry. A New Program Redesigns the Degree to Match.
A $47 million pilot aligns PhD training with where graduates actually go. Whether it fixes the cause or just adapts to the symptom is the open question.
General AI Outscored Clinical AI on Medical Tests. That Says Less About the AI Than About the Tests.
A closely watched study found frontier chatbots beating specialized clinical tools. The result is statistically borderline, and a weak proxy for which tool is actually safer.
China Now Runs More Early-Stage Drug Trials Than the U.S. America's Distinctive Answer Isn't Scale. It's a System That Remembers Every Patient for Life.
The VA's edge in the biotech competition with China isn't its 9 million patients. It's decades of continuous, linked data no fragmented system can replicate.
Replimune's Melanoma Drug Has Impressive Survival Numbers. The FDA Says That's Not Proof It Works.
A single-arm combination trial produced encouraging survival data the FDA still calls "not interpretable." Both statements are true at once.
GSK Doubled Its Plan for Late-Stage Drug Trials and Wrote Off a Failed One, in the Same Report
Running more Phase 3 trials guarantees more expensive failures. A £1.3 billion writedown is the cost of that strategy, not a sign it's failing.
A Diabetes Group Had Researchers Removed for Handing Out an Editorial. It Did It Again a Month Later.
Every attempt by the ADA to contain a controversy over federal research funding made the story bigger, twice.
The Approved Alzheimer's Drugs Have a Dangerous Side Effect. This Company Is Betting It Comes From Hitting the Wrong Target.
Early blinded data hint at an amyloid antibody without the brain-swelling risk. The efficacy question is still a year away.
For 90 Years, a Hormonal Disorder Was Named After a Symptom Most Patients Don't Have
PCOS's rename to PMOS corrects a name that trained doctors to look for a feature most patients never had.
We Can Now Detect Alzheimer's a Decade Early With a Blood Test. We Still Can't Do Much About It.
Detection has outrun treatment, and who builds the infrastructure to act on an early diagnosis is now a business question.
Half a Dozen Companies Are Racing to Cure the Same Rare Disease. The Disease Is Almost Beside the Point.
A single shared mutation made one rare disease the cleanest proving ground for competing gene-editing platforms.
The Government Spent Two Decades and Billions Trying to Connect Health Records. Now It Is Asking Companies to Promise.
More than 700 organizations have signed voluntary pledges after two mandates and $35 billion largely failed to fix interoperability.
Sarepta Replaced a Dealmaker CEO With a Scientist. That Choice Is the Whole Message.
A physician-scientist replaces a longtime commercial CEO after a gene-therapy safety crisis. The choice is itself a signal.
The Company Says Its Trial Hit Its Goal. The FDA Says It Failed. Both Are Describing the Same Data.
Capricor's Duchenne heart-therapy data and the FDA's briefing documents reach opposite verdicts from the same trial.
argenx Paid $2.2 Billion for Two Small Trials. The Same Drug Target Already Has a Graveyard Entry.
A steep premium for an early-stage autoimmune antibody, and the previous company that walked away from the same target.
A Drug Roche Gave Up On Is Going Public Through a SPAC. The Story Is Bigger Than One Company.
A rescued Angelman syndrome drug, a three-way race, and the hard part of telling a hidden gem from a lesson.
AstraZeneca Beat on Cancer Drugs. Cancer Drugs Are Now Almost Half the Company.
Oncology is carrying the whole company while three other divisions decline, ahead of an ambitious 2030 target.
The Danger of Kids' E-Bikes Isn't That They Crash. It's That They Broke the Link Between a Child's Body and Their Speed.
Pediatric e-bike injuries have surged past 300% at some trauma centers, and the physics explains why.
Everyone Agrees Doctors Should Learn More Nutrition. The Quiet Question Is Whether 40 Hours Fixes Anything.
A rare bipartisan medical-school pledge, and why counting hours may be the wrong way to measure whether it works.
The US Just Dropped Below the Measles Vaccination Threshold. The National Number Hides Where the Danger Actually Is.
Measles doesn't spread through a national average. It spreads through specific under-vaccinated communities the average can't show you.
A Lettuce Parasite Is Sickening Thousands, and It Exposes a Tension in "Just Eat Real Food"
The systems that make fresh produce safe to eat are the same systems currently being scaled back.
Med-Tech Was Priced on Endless Procedure Growth. Two Forces Are Testing That at Once.
Boston Scientific is down more than 50% this year while analysts stay bullish. The real question is how much of the volume weakness is deferral versus permanent substitution.
The New Medical School Loan Caps Are the Headline. The Residency Years Are Where the Math Actually Breaks.
Federal loan caps get the attention, but the bigger risk is private debt without income-based repayment during years when resident pay stays fixed near $65,000.
Sanofi Says Lantus Pen Supply Is "Intermittent." The FDA Doesn't List It as a Shortage. Both Are True.
A competitor's exit left patients unable to fill routine insulin prescriptions, even though the national supply of insulin glargine looks adequate on paper.
The US Is Reshoring Drug Ingredient Production. The Chemicals Those Plants Start From Still Come From China.
Reshoring campaigns target the visible API layer while China's real chokepoint sits two steps lower, in starting materials nobody is building here.
A Federal Men's Health Office Has Failed for Two Decades. This Version Asks a Question the Others Skipped.
A new Senate bill commissions a GAO study before building the office it proposes, addressing the strongest objection prior attempts never answered.
Two Public Health Nominations Stalled in the Same Committee on the Same Day. Only One Was About Attendance.
Erica Schwartz's CDC nomination hit a quorum problem. Sean Kaufman's nomination hit something else, and the difference is worth reading closely.
The FDA Says It Can't Reliably Tell What "BPC-157" Is. Its Advisory Panel Voted to Allow Compounding It Anyway.
An advisory committee broke with FDA scientists who found the name on the vial doesn't reliably identify one molecule, the precondition for every other safety question.
The EU Has Required Clinical Trial Results Since 2014. It's Only Now Building the System to Notice Who Doesn't File.
EMA just added reminder emails and a compliance dashboard. That such basic monitoring didn't already exist explains a decade of unenforced disclosure rules.
Lilly's Triple Agonist Improved Every Cardiovascular Risk Marker. The Trial Couldn't Show It Prevented Heart Attacks.
Retatrutide cut triglycerides, cholesterol, and CRP, but the cardiovascular outcomes trial was never powered to detect a difference in heart attacks and strokes.
The White House Wants to Fund Scientists Instead of Universities. Scientists Need Somewhere to Work.
A sweeping science-funding overhaul wants to move money from institutions to individuals while also cutting indirect costs, and the two reforms fight each other.
Congress Is Advancing Warning Labels for a Food Category That Has No Legal Definition Yet
The Senate voted to require warning labels on ultra-processed foods, then tasked a future panel with defining what that category actually means.
A Nation's Team Losing on Penalties Is One of the Few Heart-Attack Spikes You Can See Coming
Hospitals record measurable cardiac spikes timed to World Cup matches. The surge is predictable, and mostly unplanned for.
The Agency That Studies How American Health Care Actually Works Just Lost $109 Million in Research
AHRQ stopped funding dozens of health services studies mid-stream. The mechanism matters as much as the money.
The First Cholesterol Pill of Its Kind Just Won Approval. Whether It Reaches Patients Is a Separate Question.
Merck's Lipfendra matches injectable PCSK9 inhibitors. The injectable versions already showed that a drug can work and still fail to reach patients.
Hospitals Are Governing AI With a Process Designed for MRI Machines. The Mismatch Is the Danger.
Most hospitals oversee clinical AI with a review process built for a technology that doesn't update itself monthly.
The Deadliest Wildfire in Modern US History Is Teaching Us That the Fire Is Only Half the Harm
The largest postfire health study in the country finds most lasting harm came from housing and job loss, not the flames.
A Device Just Restored Reading Vision to Blind Patients. Americans Will Wait Years for It.
A retinal chip restored reading vision to macular degeneration patients in Europe. The US gap is wider than the coverage suggests.
The Medicaid Fight Isn't Really About $1 Billion. It's About When the Government Gets to Hold the Money.
HHS deferred over $1 billion in Medicaid payments pending fraud documentation. The procedural question underneath will outlast this dispute.
23 Million Americans Are Staying in Jobs They Want to Leave. The System Is Working as Designed.
Job lock isn't a malfunction. It's employer-based insurance doing exactly what it was built to do.
Orphan Drug Status Has Become the Most Valuable Regulatory Designation in Pharma
Rare disease companies keep winning pricing exemptions. Each carve-out is defensible. Together they are redirecting where the industry spends its research money.
The Hard Part of Curing Rare Diseases Is No Longer the Science
A new nonprofit is built on the premise that gene editing already works, and the reason so few children get it is that every therapy is built from scratch.
Congress Rejected the HIV Prevention Cuts in January. The Money Still Isn't Going Out.
Lawmakers preserved $1.384 billion in CDC prevention funding. Six months later, OMB declined to renew $46 million for a prevention program anyway.
The FDA Made Two Changes to Testosterone Labels. Only One Was Backed by New Evidence.
One removed a disproven prostate cancer warning. The other removed a statement that benefits were unproven in older men, which no new evidence overturned.
The Lettuce Never Tested Positive. The Recall Is Still Right.
FDA's one positive Cyclospora sample was a false positive. The recall stands anyway, because outbreak investigations run on epidemiology, not lab results.
Medicare Pays About $10 for a Conversation That Could Add Years to Someone's Life
A proposed 19.1% increase would raise tobacco cessation counseling to roughly $12. That's the right direction, and probably not enough to change the arithmetic.
The Air You Breathe and the Air the Law Recognizes Are Drifting Apart
A Clean Air Act provision lets states delete wildfire smoke readings from compliance records. Fifty EPA monitors hit hazardous levels in a single day this month.
The Pentagon Will Screen Troops for Low Testosterone. Screening and Diagnosing Are Not the Same Thing.
Guidelines recommend treatment only for confirmed deficiency and symptoms. Screening finds asymptomatic cases, in an occupation that lowers testosterone by design.
Pandemic Preparedness Is Already Being Treated as National Security. That Framing Funds Some Things and Starves Others.
Securitization reliably funds countermeasures and detection. It reliably does not fund the public health capacity that determined how Covid actually went.
Three Drugmakers Have Announced Pharma's "Largest" AI Supercomputer in Nine Months
Bristol Myers Squibb's claim contains four qualifiers. What's verifiable, and more interesting, is a 55% cost reduction and a specific bet about where compute helps.
Nonprofit Hospitals Hold $300 Billion in Investments. They're Moving It Into Assets They Can't Sell Quickly.
Portfolios are shifting into private equity and hedge funds, exactly the assets that lock up when markets seize, while investment income is nearly half of net income.
Medicare's 2027 Physician Pay Cut Isn't a Cut. It's a Patch Expiring, and a Permanent Fork Opening.
The decline comes entirely from a one-year congressional increase lapsing, while a separate two-track payment structure quietly widens every year, forever.
Medicare's New Mandatory Surgery Bundle Puts Hospitals at Risk for What Happens After Discharge
For most TEAM procedures, post-acute care is a minor cost. For hip fracture patients, the frailest in the model, it's 54%.
UnitedHealth's Profits Jumped While It Lost 525,000 Members. Those Facts Are Connected.
The CFO said the margin gain wasn't from costs coming under control, it was from exiting members and plans priced below cost.
Hospitals Are Starting to Subscribe to Their Medical Equipment Instead of Buying It
GE HealthCare's $500 million, 10-year deal with Catholic Health turns capital equipment into something closer to a subscription.
A Surgical Robot Company Just Gave Us the Clearest Evidence Yet That People Are Skipping Care
Intuitive Surgical beat earnings and its stock fell anyway, because US procedure growth slowed as ACA subsidies lapsed.
Private Equity Used to Outbid Hospitals for Medical Practices. In 2026 That Flipped.
PE deal volume hit a five-year high while its valuations collapsed from 15.3x to 10.7x, and strategic buyers now pay more.
"Capture the Full Patient Story" Is the Most Consequential Phrase in Health Tech Right Now
Generative AI that finds missed documentation and AI that maximizes billing intensity are the same product, distinguishable only by whether the facts support the code.
Nevada's Governor Race Turns on Health Care Costs. How Much Can a Governor Actually Control?
Joe Lombardo and Aaron Ford are both promising to fix health care affordability. Here's what a Nevada governor can and cannot actually control.
Doctors Use 800 Clinical Calculators Daily. Some Were Built on Studies of Five People.
MDCalc is launching quality ratings for the clinical tools millions of physicians consult, scoring validation, usability, and embedded bias.
The Miracle That Doesn't Scale
ARPA-H just put $160 million behind custom gene editing, inspired by the baby who was saved by it.
The Most Measured Man Alive Missed It for Ten Years
Bryan Johnson spends a fortune tracking his own biology. An autoimmune disease still hid inside him for a decade.
Family Caregivers Face Ruin as States Cut Medicaid Wages
Several states want to slash the pay of parents and relatives who care for people with disabilities, ahead of a $1 trillion federal Medicaid cut.
Radiologists Have Been Using AI for Years. Now It's Learning to Write.
The FDA just granted Breakthrough Device status to two AI systems that draft chest X-ray reports, not just flag abnormalities on them.
As Infectious Threats Reappear, U.S. Public-Health Cuts Face a Real-World Test
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.